Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative study of acarbose, vildagliptin, and saxagliptin in type 2 diabetes mellitus
ChiCTR2000040826Phase 4Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Oct 2015
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of acarbose, vildagliptin and saxagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Flora change at 12 weeks, HbA1c at 12 weeks and 1 more. Started Oct 2015; status: completed.
02
Drugs
acarbosevildagliptinsaxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2000040826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040826.